Go to content
UR Home

Hyperfractionated accelerated radiation therapy plus cetuximab plus cisplatin chemotherapy in locally advanced inoperable squamous cell carcinoma of the head and neck

Kuhnt, Thomas ; Schreiber, Andreas ; Pirnasch, Anett ; Hautmann, Matthias G. ; Hass, Peter ; Sieker, Frank P. ; Engenhart-Cabillic, Rita ; Richter, Michael ; Dellas, Kathrin ; Dunst, Jürgen


Background Cetuximab (CET) is a potent inhibitor of the epidermal growth factor receptor and has been shown to have activity in squamous cell carcinoma of the head and neck (SCCHN). We conducted a single-arm phase II trial of a combination therapy comprising cisplatin (CIS), CET and hyperfractionated accelerated radiotherapy (HART). Patients and methods Patients with UICC stage III or IVA/B, M0 ...


Owner only: item control page
  1. Homepage UR

University Library

Publication Server


Publishing: oa@ur.de

Dissertations: dissertationen@ur.de

Research data: daten@ur.de

Contact persons